NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
The filing target moves from December 2026 to March 2027 to include additional trial data.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroSense Therapeutics (NRSN) plans to expand its PrimeC application for ALS in Canada, targeting a March 2027 filing.
The target replaces December 2026 to incorporate new data; Health Canada confirmed no concerns with the revised timing. The package will combine published Phase 2b PARADIGM results with a new analysis of neurofilament light chain (NfL), a measure of neuronal injury, and additional unpublished trial data. PrimeC-treated participants showed greater NfL reductions than placebo, with a more pronounced effect in participants with higher baseline functionality. Further statistical analyses are underway. The pre-submission process is complete, with alignment on proposed content and structure. This would be PrimeC's first marketing application in any jurisdiction.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Minor pointPrimeC-treated participants showed greater NfL reductions than placebo, more pronounced among participants with higher baseline functionality.
- Minor pointPre-submission process completed, with Health Canada alignment on proposed submission content and structure.
- Minor point. Forward-looking: it has not happened yet and may not happen.Expanded submission package is planned to include new NfL analysis and additional unpublished PARADIGM data.
- Minor pointPotential Canadian commercialization partners are in discussions with NeuroSense.
- Minor pointFDA-cleared U.S. Phase 3 PARAGON trial preparation is underway.
Negative
- Moderate pointMarch 2027 filing target replaces December 2026 to allow inclusion of additional data.
- Minor pointAdditional statistical analyses remain underway to characterize NfL findings and support their inclusion in the submission.
Details
Market move: NRSN -7.04% vs previous close. Canadian ALS filing update
On Nov 2, the day this news came out, the latest delayed price for NRSN is 7.04% below the previous close. Argus tracked a trough of -15.4% from its starting point during tracking. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $1.85.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Health Canada filing target
- March 2027
- NDS target; updated from December 2026
- Standard review target
- Approximately 300 calendar days
- Health Canada NDS review, following acceptance
- Canadian ALS population
- Approximately 4,000 Canadians
- Population PrimeC could address if approved
- Annual new diagnoses
- Approximately 1,000
- New ALS diagnoses in Canada each year
Historical Context
-
Earlier report gave a December 2026 Health Canada NDS target, now revised to March 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
neurofilament light chain medical
new drug submission regulatory
amyotrophic lateral sclerosis medical
biomarker medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expanded package to include new neurofilament light chain (NfL) analysis; Health Canada confirms March 2027 filing timeline
Submission would be PrimeC's first marketing application in any jurisdiction, potentially addressing approximately 4,000 Canadians living with ALS
The March 2027 filing target updates the previously announced December 2026 timetable, allowing the additional data to be included. Health
The planned filing follows completion of the pre-submission process and alignment with Health Canada on the proposed submission content and structure. The expanded package will combine the Phase 2b PARADIGM results published in JAMA Neurology with a new neurofilament light chain (NfL) analysis and additional unpublished data from the Phase 2b PARADIGM trial. The Company expects the NfL analysis to provide further biomarker evidence supporting the clinical findings observed in PARADIGM. In the new analysis, PrimeC-treated participants demonstrated a greater reduction in NfL compared to placebo, with an even more pronounced effect observed in participants with higher baseline functionality. Additional statistical analyses are underway to further characterize these findings and support their incorporation into the planned submission to Health Canada.
Following acceptance of the NDS for review, Health Canada's standard review target for an NDS is approximately 300 calendar days. If approved, PrimeC would receive its first regulatory authorization and would address a population of approximately 4,000 Canadians living with ALS, with approximately 1,000 new diagnoses each year. In parallel, the Company is advancing discussions with potential commercialization partners for
"Neurofilament light chain is one of the most widely used measures of neuronal injury in ALS, and adding this analysis to the PARADIGM results gives Health Canada a broader body of evidence on which to evaluate PrimeC's potential benefit for people living with ALS," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "
About NeuroSense
NeuroSense Therapeutics is a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
Results from NeuroSense's Phase 2b PARADIGM study of PrimeC in ALS have been published in JAMA Neurology.
NeuroSense has received clearance from the
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to target several key mechanisms that contribute to neuronal degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation, with the potential to inhibit disease progression.
About ALS
Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes progressive paralysis and, typically, death within 3 years of symptom onset. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "may," "plan," "potential," "target," "will," or similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements regarding the Company's planned New Drug Submission (NDS) to Health Canada for PrimeC, the anticipated timing of such submission, the completion and incorporation of additional clinical and biomarker analyses, including neurofilament light chain (NfL), the potential contribution of such analyses to the regulatory assessment of PrimeC, the anticipated regulatory review process and timelines, the Company's discussions with potential commercialization partners for Canada, the potential patient population for PrimeC and estimated annual ALS diagnoses in Canada, and the Company's plans to advance its Phase 3 PARAGON clinical trial in ALS. Forward-looking statements are based on the Company's current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, delays in completing the additional analyses or preparing and submitting the NDS, the possibility that the additional data may not provide the anticipated supporting evidence, uncertainties regarding the acceptance, review, timing and outcome of the NDS, the possibility that Health Canada may request additional information or clinical studies, delays in initiating or conducting the PARAGON trial, the possibility that the Company will not enter into a commercialization partnership for Canada on acceptable terms, or at all, uncertainty in estimates of ALS incidence and the potential patient population in Canada, the Company's ability to obtain sufficient financing to support its operations and clinical development programs, the Company's ability to maintain its listing on Nasdaq and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission (SEC). There can be no assurance that the NDS will be submitted within the anticipated timeframe, that Health Canada's review will be completed within the standard review period, or that PrimeC will receive regulatory approval. Additional information concerning these and other risks is included under "Risk Factors" in the Company's Annual Report on Form 20-F filed with the SEC on March 31, 2026, and in its subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurosense-to-strengthen-primec-canadian-als-submission-with-new-nfl-data-302926488.html
SOURCE NeuroSense
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does NeuroSense plan to file PrimeC for approval in Canada?
NeuroSense targets March 2027 for its PrimeC New Drug Submission to Health Canada, replacing the previously announced December 2026 timetable. Health Canada confirmed it has no concerns with the revised timing. The submission would be PrimeC's first marketing application in any jurisdiction.
What did NeuroSense's new PrimeC NfL analysis show?
PrimeC-treated participants demonstrated a greater reduction in NfL than placebo, with a more pronounced effect among participants with higher baseline functionality. NfL is a measure of neuronal injury. Additional statistical analyses are underway to further characterize the findings.
How long would Health Canada review NeuroSense's PrimeC application?
Following acceptance of the submission for review, Health Canada's standard review target is approximately 300 calendar days. Approval would give PrimeC its first regulatory authorization; the review target is not an approval date.